Lupvindol Bioscience Ltd

Dr. Hunter Land, PhD, MS, is a seasoned expert in scientific research and development strategy, with a career spanning two decades and encompassing work across more than 25 therapeutic areas. Over the past 12 years, he has become a leading figure in cannabinoid research, playing a pivotal role in the development of groundbreaking therapies. Notably, Dr. Land oversaw large-scale R&D initiatives that led to the FDA approval of Epidiolex, the first plant-derived cannabinoid medication to receive FDA approval. Currently serving as CEO of Lupvindol Bioscience, Dr. Land guides a team of world leading professionals in the rapid development of innovative, patent-protected medicines aimed at addressing critical unmet medical needs. His pioneering work and commitment to improving human and animal health continues to shape the future of cannabinoid-based therapeutics.

At BRC, one of the select DEA Schedule I, FDA-compliant cannabinoid research companies, Dr. Land initiated four FDA-approved Investigational New Drug (IND) clinical trials with cannabinoid-based therapeutics. His previous roles include serving as Senior Scientific Director and Director of Cannabinoid Research at Canopy Growth Corporation, previously the world's largest cannabis producer, and as GW Pharma's first full-time R&D employee in the US, where he was instrumental in developing Epidiolex® and Sativex® including co-authorship of protocols for treating refractory epilepsy, multiple sclerosis, and pain.

Dr. Land's contributions to the field are widely recognized. He has presented at over 50 scientific conferences, is a named inventor on 15 patent applications, and has authored more than 20 publications. He is a guest lecturer at the University of Wisconsin and the University of Colorado Skaggs School of Pharmacy, and has been featured in Forbes and Entrepreneur as a leading cannabinoid expert.